EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy

Mya Bojarsky, Julia A Baran iD, Stephen Halada, Amber Isaza, Hongming Zhuang, Lisa States, Frederick D Grant, Stephanie Robbins, Lindsay Sisko, Julio C Ricarte-Filho, Ken Kazahaya, N Scott Adzick und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.11.2023 · 108 (12) · 3338-3344

DOI: 10.1210/clinem/dgad322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.06.2023. Verfasst von Mya Bojarsky und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetes, The Thyroid Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Children's Hospital of Philadelphia Frontier Program, The Children’s Hospital of Philadelphia Frontier Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The American Thyroid Association (ATA) Pediatric Guidelines recommend patients not receive radioactive iodine therapy (RAIT) for differentiated thyroid cancer (DTC) confined to the thyroid. Since publication, there is ongoing concern whether withholding RAIT will result in a lower rate of remission.

Objective

This study explores whether ATA low-risk patients treated with and without RAIT achieved similar remission rates.

Methods

Medical records of patients <19 years old diagnosed with DTC and treated with total thyroidectomy between 2010 and 2020 were reviewed. Multivariate logistic regression was performed to evaluate factors influencing RAIT administration and remission rate.

Results

Ninety-five patients with ATA low-risk DTC were analyzed: 53% (50/95) and 47% (45/95) were treated with and without RAIT, respectively. RAIT was used to treat 82% of patients before 2015 compared with 33% of patients after 2015 (P < .01). No significant difference in 1-year remission rate was found between patients treated with and without RAIT, 70% (35/50) vs 69% (31/45), respectively. With longer surveillance, remission rates increased to 82% and 76% for patients treated with and without RAIT, respectively. Median follow-up was 5.8 years (IQR 4.3-7.9, range 0.9-10.9) and 3.6 years (IQR 2.7-6.6; range 0.9–9.3) for both cohorts. No risk factors for persistent or indeterminate disease status were found, including RAIT administration, N1a disease, and surgery after 2015.

Conclusion

Withholding RAIT for pediatric patients with ATA low-risk DTC avoids exposure to radiation and does not have a negative impact on remission rates. Dynamic risk stratification at 1-year after initial treatment is a suitable time point to assess the impact of withholding RAIT for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinomaHumansChildYoung AdultAdultIodine RadioisotopesThyroidectomyRisk FactorsRetrospective Studies

Stichwörter der Autor:innen

pediatric thyroid cancerradioactive iodine therapythyroid cancer

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Division of Endocrinology and Diabetes, The Thyroid Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Division of Nuclear Medicine, Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Section Oncologic Imaging, Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Division of Pediatric Otolaryngology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

ORCID-Profile: Julia A Baran, Andrew J Bauer

Förderung

  • The Children's Hospital of Philadelphia Frontier Program
  • The Children’s Hospital of Philadelphia Frontier Program

Zitieren

APA

Bojarsky, M., Baran, J. A., Halada, S., Isaza, A., Zhuang, H., States, L., Grant, F. D., Robbins, S., Sisko, L., Ricarte-Filho, J. C., Kazahaya, K., Adzick, N. S., Mostoufi-Moab, S., & Bauer, A. J. (2023). Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy. The Journal of Clinical Endocrinology & Metabolism, 108(12), 3338-3344. https://doi.org/10.1210/clinem/dgad322

Vancouver

Bojarsky M, Baran JA, Halada S, Isaza A, Zhuang H, States L, et al. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy. The Journal of Clinical Endocrinology & Metabolism. 2023;108(12):3338-3344. doi:10.1210/clinem/dgad322

BibTeX
@article{Bojarsky2023,
  author = {Bojarsky, Mya and Baran, Julia A and Halada, Stephen and Isaza, Amber and Zhuang, Hongming and States, Lisa and Grant, Frederick D and Robbins, Stephanie and Sisko, Lindsay and Ricarte-Filho, Julio C and Kazahaya, Ken and Adzick, N Scott and Mostoufi-Moab, Sogol and Bauer, Andrew J},
  title = {Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {12},
  pages = {3338--3344},
  doi = {10.1210/clinem/dgad322}
}
Kostenlos starten →